Log in

Relevant bibliographies by topics / Intravitreal bevacizumab / Journal articles

To see the other types of publications on this topic, follow the link: Intravitreal bevacizumab.

Journal articles on the topic 'Intravitreal bevacizumab'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Intravitreal bevacizumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shahid, Muhammad Hamza, Faisal Rashid, Saba Tauqeer, Rabab Ali, Muhammad Talha Farooq, and Nouman Aleem. "Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab only in Treatment of Refractory Diabetic Macular Edema." Pakistan Journal of Medical and Health Sciences 16, no. 6 (2022): 301–3. http://dx.doi.org/10.53350/pjmhs22166301.

Full text

Abstract:

Background: Macular edema due to diabetic retinopathy is among the most common causes of blindness in diabetics from working age group around the world . Diabetic macular edema which involves the center of the macula is among the major cause of visual decline in patients with diabetes mellitus. Intra-Vitreal Triamcinolone Acetonide with intravitreal Bevacizumab and intravitreal Bevacizumab only have been in practice as treatment options for cases not responsive to anti-vascular endothelial growth factor agents. Objective: To compare safety and efficacy profile of suprachoroidal injection of tr

APA, Harvard, Vancouver, ISO, and other styles

2

Hussein, Zaid R. "Indications of Intravitreal Injection of Bevacizumab in a sample of Iraqi patients." AL-Kindy College Medical Journal 14, no. 2 (2019): 79–83. http://dx.doi.org/10.47723/kcmj.v14i2.57.

Full text

Abstract:

Background: Anti-vascular endothelial growth factors commonly used intravitreally for treatment of variable retinal disease worldwide, which help to regulate the upregulation of vascular endothelial growth factors due to ischemia or/and other retinal insult. Objective: To review all cases of intravitreal bevacizumab given in the retinal unit of the Eye Specialty Private Hospital in Iraq from December 2015 to June 2016, pointing out the common indications. Methods: A retrospective study including all cases of intravitreal injections of bevacizumab recorded at the Eye Specialty Priva

APA, Harvard, Vancouver, ISO, and other styles

3

Sethi, Muhammad Junaid, Umer Khan, Natasha Junaid, Nazli Gul, Ishan Ullah, and Muhammad Israr. "Visual Results of Intravitreal Bevacizumab (Avastin) Treatment for Branch Retinal Vein Occlusion a Multi Center Study." Pakistan Journal of Medical and Health Sciences 17, no. 2 (2023): 811–13. http://dx.doi.org/10.53350/pjmhs2023172811.

Full text

Abstract:

Objective: To evaluate the visual outcomes in patients with branch retinal vein obstruction after intravitreal bevacizumab (Avastin) injection. Study Location and Duration:, Department of Ophthalmology Abaseen hospital and Khyber medical center Peshawar from January 2019 to January 2022 both department conducted this multi-center study. Methodology: Patients with BRVO received at least one intravitreal Bevacizumab (Avastin) injection of 1.25 mg in 0.05 ml. Snellen visual acuity tests, Fundus Fluorescein Angiography (FFA), and Optical Coherence Tomography were used to assess the patients (OCT).

APA, Harvard, Vancouver, ISO, and other styles

4

Peters, Swaantje, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, and Ulrich Schraermeyer. "Penetration of Bevacizumab into the Iris, Anterior Chamber Angle and Ciliary Body After Intravitreal Injection." European Ophthalmic Review 03, no. 01 (2009): 36. http://dx.doi.org/10.17925/eor.2009.03.01.36.

Full text

Abstract:

Recently, it was suggested that the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab could be used in the treatment of rubeosis iridis. Therefore, we aimed to trace the penetration of bevacizumab into the anterior chamber after intravitreal injection of the drug. We found that intravitreally injected bevacizumab penetrates well and quickly into the anterior chamber angle, iris and ciliary body. The highest concentration of bevacizumab is present on days one to four after injection, with penetration into the iris appearing to be faster than that into the anterior chamber angl

APA, Harvard, Vancouver, ISO, and other styles

5

Lucas, Raj S., Hamish D. R. McKee, and Lawrence R. Lee. "Intravitreal Bevacizumab." Ophthalmology 114, no. 2 (2007): 400. http://dx.doi.org/10.1016/j.ophtha.2006.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Khamar, BakuleshM. "Intravitreal bevacizumab." Indian Journal of Ophthalmology 66, no. 1 (2018): 173. http://dx.doi.org/10.4103/ijo.ijo_802_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

An, Seoung Hyun, and Woo Jin Jeong. "Early-scatter laser photocoagulation promotes the formation of collateral vessels in branch retinal vein occlusion." European Journal of Ophthalmology 30, no. 2 (2019): 370–75. http://dx.doi.org/10.1177/1120672119827857.

Full text

Abstract:

Purpose: To investigate the effect of early-scatter laser photocoagulation on the formation of collateral vessels in branch retinal vein occlusion. Methods: The medical records of 40 cases (40 patients) of branch retinal vein occlusion with macular edema were retrospectively reviewed. Of them, 23 patients were treated with intravitreal bevacizumab injection and 17 patients underwent intravitreal bevacizumab injection with additional laser treatment. Early-scatter laser photocoagulation was applied for capillary non-perfusion areas, regardless of retinal neovascularization. Collateral vessel pr

APA, Harvard, Vancouver, ISO, and other styles

8

Newcott, Eric K., Abdallah A. Ellabban, Shokufeh Tavassoli, and Ahmed Sallam. "Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy." Case Reports in Ophthalmological Medicine 2015 (2015): 1–3. http://dx.doi.org/10.1155/2015/713868.

Full text

Abstract:

Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable option

APA, Harvard, Vancouver, ISO, and other styles

9

Shrestha, Arjun, Rinkal Suwal, Rajan Shrestha, Barsha Suwal, and Deepak Khadka. "Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study." Journal of Nepal Medical Association 59, no. 241 (2021): 858–61. http://dx.doi.org/10.31729/jnma.5515.

Full text

Abstract:

Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital. Methods: This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal

APA, Harvard, Vancouver, ISO, and other styles

10

Ehrlich, Rita, Russell Pokroy, Ori Segal, et al. "Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)." European Journal of Ophthalmology 29, no. 2 (2018): 229–33. http://dx.doi.org/10.1177/1120672118782102.

Full text

Abstract:

Purpose: To evaluate the outcome of second-line intravitreal ranibizumab treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal bevacizumab. Methods: Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal bevacizumab injections prior to intravitreal ranibizumab, at least three-monthly intravitreal ranibizumab injections and at least 12 months of follow-up were i

APA, Harvard, Vancouver, ISO, and other styles

11

Cervantes-Castañeda, Rene A., Gian Paolo Giuliari, Michael J. Gallagher, et al. "Intravitreal Bevacizumab in Refractory Uveitic Macular Edema: One-year Follow-up." European Journal of Ophthalmology 19, no. 4 (2009): 622–29. http://dx.doi.org/10.1177/112067210901900417.

Full text

Abstract:

Purpose Uveitis is a major cause of ocular morbidity in developed countries. It has been demonstrated that macular edema is a significant cause of decreased visual acuity and macular edema in these patients. In this article, we evaluate the long-term outcome of intravitreal bevacizumab in the treatment of refractory uveitic macular edema. Methods In this retrospective, noncomparative, interventional case series, uveitic patients with macular edema who were refractory to conventional therapy and who were treated with intravitreal bevacizumab were identified and assessed. Best-corrected visual a

APA, Harvard, Vancouver, ISO, and other styles

12

Singh, Samya, Sandeep Saxena, Levent Akduman, and Carsten H. Meyer. "Off-label use of intravitreal bevacizumab: A global conundrum." Indian Journal of Ophthalmology 72, no. 5 (2024): 617–19. http://dx.doi.org/10.4103/ijo.ijo_2166_23.

Full text

Abstract:

Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab’s off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.

APA, Harvard, Vancouver, ISO, and other styles

13

Sandra, Melvina Nidya, Yumni Shabrina, Tri Wahyu Widayanti, et al. "CENTRAL MACULAR THICKNESS AFTER COMBINED THERAPY OF BEVACIZUMAB INTRAVITREAL INJECTION AND TOPICAL DICLOFENAC COMPARED WITH BEVACIZUMAB INTRAVITREAL INJECTION ALONE IN DIABETIC MACULAR EDEMA." International Journal of Retina 4, no. 2 (2021): 106. http://dx.doi.org/10.35479/ijretina.2021.vol004.iss002.164.

Full text

Abstract:

Introduction: To evaluate whether the combination of diclofenac eye drops and bevacizumab intravitreal injection would provide additional benefits over bevacizumab alone in the treatment of naïve diabetic macular edema (DME). Methods: A total of 43 patients were enrolled consecutively and randomized into two groups to receive combination treatment with intravitreal bevacizumab and topical diclofenac (group 1) or bevacizumab alone (group 2). Group 1 patients received single bevacizumab intravitreal injection and got self-administered diclofenac eye drop four times daily for one month. Gro

APA, Harvard, Vancouver, ISO, and other styles

14

TAŞDEMİR ARI, Aysun, Mustafa BERHUNİ, Gizem GÜRBOSTAN SOYSAL, and Nesime Setge TISKAOĞLU. "Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital." Journal of Health Sciences and Medicine 7, no. 1 (2024): 13–16. http://dx.doi.org/10.32322/jhsm.1367325.

Full text

Abstract:

Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found

APA, Harvard, Vancouver, ISO, and other styles

15

Weinstein, Orly, Muhammad Abu Tailakh, Tova Lifshitz, Victor Novack, and Jaime Levy. "Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events." European Journal of Ophthalmology 30, no. 1 (2019): 66–71. http://dx.doi.org/10.1177/1120672118823128.

Full text

Abstract:

Background: Systemic complications of intravitreal anti-vascular endothelial growth factor agents are relatively uncommon but highly significant. Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. Secondary objective: To analyze the association between injection frequency and the risk for thromboembolic events, the time interval between the injection and the thromboembolic events, and the influence of chronic diseases on complications

APA, Harvard, Vancouver, ISO, and other styles

16

Pradhan, Eli, Sushma Duwal, Sanyam Bajimaya, et al. "Acute Endophthalmitis after Intravitreal Bevacizumab Injections at The Tertiary Centre in Nepal." Nepalese Journal of Ophthalmology 10, no. 1 (2018): 107–10. http://dx.doi.org/10.3126/nepjoph.v10i1.21727.

Full text

Abstract:

Introduction: There are many reports of endophthalmitis following Anti- VEG F use in developed countries and from India, but there are none from Nepal yet. Therefore, the aim of this study was to report the prevalence and management of acute endophthalmitis after intravitreal injection of bevacizumab.Methods: This is a clinical, retrospective, non-comparative study, performed in Tilganga Institute of Ophthalmology, Kathmandu, Nepal from Jan 2015 till Dec 2016. All consecutive cases of intravitreal 1.25 mg of bevacizumab injections during the study period were collected from Bevacizumab registr

APA, Harvard, Vancouver, ISO, and other styles

17

., Ankur, Yogesh Kumar, Deepesh Arora, Rupali Tyagi, and Sanjeev Kumar Mittal. "Fundus fluorescein angiographic assessment of patients with proliferative Diabetic Retinopathy and Macular Edema before and after intravitreal injection of Bevacizumab." International Journal of Research in Medical Sciences 7, no. 11 (2019): 4111. http://dx.doi.org/10.18203/2320-6012.ijrms20194976.

Full text

Abstract:

Background: To assess the role of intravitreal bevacizumab (1.25 mg) in patients with proliferative diabetic retinopathy with macular edema in terms of change in leakage area and best-corrected visual acuity.Methods: This prospective randomized interventional study was conducted in the Department of Ophthalmology from September 2013 to August 2015 and included thirty eyes of twenty patients.After a detailed history and ocular examination, diagnosed cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) underwent sequential fundus fluorescein angiography. Bevacizumab

APA, Harvard, Vancouver, ISO, and other styles

18

Erba, Stefano, Antonio Scialdone, and Giuseppe Casalino. "Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling." Medical Hypothesis, Discovery & Innovation in Ophthalmology 9, no. 3 (2020): 179–84. http://dx.doi.org/10.51329/mehdiophthal1404.

Full text

Abstract:

Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors represent the mainstay of neovascular age-related macular degeneration (nAMD) treatment. Although bevacizumab has been the first anti-VEGF used in ophthalmology, it is unlicensed for intraocular use. However, the favourable cost-benefit balance has favoured its widespread use. We aimed to present relevant literature regarding the safety profile and the regulatory issues of intravitreal bevacizumab use. Methods: In this narrative review we report relevant studies regarding the safety profile of intravitreal beva

APA, Harvard, Vancouver, ISO, and other styles

19

Cai, Cindy X., Marguerite O. Linz, and Adrienne W. Scott. "Intravitreal Bevacizumab for Proliferative Sickle Retinopathy: A Case Series." Journal of VitreoRetinal Diseases 2, no. 1 (2017): 32–38. http://dx.doi.org/10.1177/2474126417738627.

Full text

Abstract:

Purpose: To report outcomes of intravitreal bevacizumab therapy for proliferative sickle retinopathy (PSR). Methods: A retrospective, interventional case series. Five eyes of 5 patients with PSR were managed with intravitreal bevacizumab therapy over a 13-year period at a single institution. Results: Four patients had sickle cell-hemoglobin SC disease and 1 had sickle cell-beta thalassemia disease. Four of the patients treated with intravitreal bevacizumab injection were treated for recurrent vitreous hemorrhage and 1 was treated for new peripheral sea fan neovascularization. In those patients

APA, Harvard, Vancouver, ISO, and other styles

20

Chalam, Kakarla V., Suzie Gasparian, and Moises Enghelberg. "Dramatic Resolution of Recalcitrant Cystoid Macular Edema after Concurrent Intravitreal Injection of Bevacizumab and Triamcinolone." Medical Hypothesis, Discovery & Innovation in Ophthalmology 9, no. 3 (2020): 159–63. http://dx.doi.org/10.51329/mehdiophthal1407.

Full text

Abstract:

Background: Cystoid macular edema (CME), a common complication of branch retinal vein occlusion (BRVO), is associated with a significant vision loss. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the gold standard of treatment, while grid macular photocoagulation has also been used as an adjuvant in patients with CME secondary to BRVO. More recent efforts were successful by the use of intravitreal triamcinolone acetonide. We proposed a concurrent use of intravitreal triamcinolone acetonide and intravitreal bevacizumab in the treatment of CME secondary to BRVO. Case prese

APA, Harvard, Vancouver, ISO, and other styles

21

Park, Min Soo, and Seung Joon Lee. "Comparison of Intravitreal Bevacizumab and Aflibercept Injections for Central Serous Chorioretinopathy." Journal of the Korean Ophthalmological Society 62, no. 7 (2021): 957–62. http://dx.doi.org/10.3341/jkos.2021.62.7.957.

Full text

Abstract:

Purpose: We examined differences in the treatment effects of intravitreal bevacizumab injections and intravitreal aflibercept injections in patients with central serous chorioretinopathy. Methods: This retrospective analysis included 51 eyes of 49 patients who received intravitreal anti-vascular endothelial growth factor agent injections after initial diagnosis with central serous chorioretinopathy. The patients were divided into two groups: one received an intravitreal bevacizumab injection, and another one received an intravitreal aflibercept injection. Patients with no reaction to treatment

APA, Harvard, Vancouver, ISO, and other styles

22

Touzani, F., C. Geers, and A. Pozdzik. "Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury." Case Reports in Nephrology 2019 (December 22, 2019): 1–4. http://dx.doi.org/10.1155/2019/2919080.

Full text

Abstract:

Introduction. Antiangiogenic agents that inhibit vascular endothelial growth factor have emerged as important tools in cancer therapy and ocular diseases. Their systemic use can induce renal limited microangiopathy. Local use of anti-VEGF agent is supposed to be safe. We report here a unique case of early endothelial cells injury induced by intravitreal injection of bevacizumab. Case Presentation. A 72-year-old man was addressed for acute kidney injury with proteinuria. He was under treatment with intravitreal injections of bevacizumab for glaucoma. Kidney biopsy was performed and electron mic

APA, Harvard, Vancouver, ISO, and other styles

23

Cunningham, William James, Eugene Michael, Sarah Welch, Niall Crosby, Benjamin Host, and Philip Polkinghorne. "The Auckland Endophthalmitis Study." Journal of VitreoRetinal Diseases 1, no. 3 (2017): 175–80. http://dx.doi.org/10.1177/2474126417690987.

Full text

Abstract:

Purpose: To report on the incidence and management of endophthalmitis following intravitreal bevacizumab in Auckland, New Zealand. Method: A survey of facilities in Auckland performing intravitreal bevacizumab between January 2007 and December 2014 was undertaken. The clinical notes of patients presenting with bevacizumab-related endophthalmitis were analyzed. Results: During the study period, 39 657 intravitreal bevacizumab injections were performed, with 21 patients undergoing treatment for bevacizumab-related endophthalmitis. The incidence of endophthalmitis was 0.053% (1 per 1888 injection

APA, Harvard, Vancouver, ISO, and other styles

24

Tarantola, Ryan M., James C. Folk, H. Culver Boldt, and Vinit B. Mahajan. "INTRAVITREAL BEVACIZUMAB DURING PREGNANCY." Retina 30, no. 9 (2010): 1405–11. http://dx.doi.org/10.1097/iae.0b013e3181f57d58.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Anwar, Faisal, Asad Aslam Khan, Tehseen Mahmood Majhu, Rana Mohammad Mohsin Javaid, Muhammad Tahir Ghaffar, and Mohammad Hasan Bokhari. "Comparison of Suprachoroidal Injection of Triamcinolone Acetonide Versus Intravitreal Bevacizumab in Primary Diabetic Macular Odema." Pakistan Journal of Medical and Health Sciences 16, no. 6 (2022): 304–6. http://dx.doi.org/10.53350/pjmhs22166304.

Full text

Abstract:

Objective: Present study aims to compare the efficacy of single dose triamcinolone acetonide suspension in suprachoroidal space and intravitreal bevacizumab in primary diabetic macular edema patients. Study design: Prospective observational study Study duration and settings: Study was conducted at department of ophthalmology, Eye Unit III, Mayo hospital Lahore (KEMU) from March 2020 to August 2020. Material and methods: The WHO calculator was used to estimate a sample size of 136 patients (66 patients in each group). Non-probability sequential sampling was used to identify patients.. Intravitr

APA, Harvard, Vancouver, ISO, and other styles

26

Yamada, Kisaburo, Kenichi Kimoto, Hirofumi Kono, and Toshiaki Kubota. "Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration." ISRN Ophthalmology 2011 (December 21, 2011): 1–4. http://dx.doi.org/10.5402/2011/916789.

Full text

Abstract:

Purpose. To report our experiences in patients with age-related macular degeneration (AMD) treated initially with intravitreal ranibizumab and then switched to bevacizumab. Methods. We retrospectively reviewed the records of 7 patients (7 eyes) who were treated with monthly injections of intravitreal ranibizumab and then switched to injections of bevacizumab (every 6 weeks) for six months. The best-corrected visual acuity measurements (BCVA) and optical coherence tomography (OCT) were performed at the baseline examination and then at each visit. The Wilcoxon signed-rank test was used for the s

APA, Harvard, Vancouver, ISO, and other styles

27

Randazzo, Alessandro, Raffaele Raimondi, Giovanni Fossati, et al. "Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis." Journal of Ophthalmology 2021 (September 9, 2021): 1–4. http://dx.doi.org/10.1155/2021/7940297.

Full text

Abstract:

Purpose. To assess real-life anatomical and functional outcomes of switch to bevacizumab in patients undergoing aflibercept intravitreal injections for nAMD. Methods. Retrospective chart review of all patients diagnosed with nAMD and undergoing intravitreal injections of aflibercept who switched to bevacizumab after the resolution XI/1986 of Lombardy Region. Results. Among 128 patients undergoing intravitreal injections, a total of 29 eyes of 29 patients met all inclusion criteria and were included in the statistical analysis. Best corrected visual acuity and central macular thickness did not

APA, Harvard, Vancouver, ISO, and other styles

28

Shrestha, Ram, Suchit Thapa Chhetri, Sagar Rajkarnikar, Sachit Dhakal, Kamala Thapa, and Sitaram Khadka. "Use of intravitreal bevacizumab among patients undergoing retinal surgical interventions in a military hospital: a descriptive cross-sectional study." Journal of Patan Academy of Health Sciences 11, no. 1 (2024): 39–43. http://dx.doi.org/10.3126/jpahs.v11i1.66397.

Full text

Abstract:

Introduction: Bevacizumab, a monoclonal antibody that hinders the activity of vascular endothelial growth factor, is extensively utilized within the field of ophthalmology. The utilization of Bevacizumab, particularly in retinal surgeries, lacks comprehensive investigation. The objective of this study is to determine the prevalence of intravitreal Bevacizumab usage in retinal surgical procedures conducted at a tertiary care center. Method: A retrospective descriptive cross-sectional study was conducted among patients who underwent retinal surgical interventions at a tertiary care center in Nep

APA, Harvard, Vancouver, ISO, and other styles

29

AKPOLAT, Çetin, Ferhat EVLİYAOĞLU, Muhammed Mustafa KURT, Burak ERDEN, and Mustafa Nuri ELÇİOĞLU. "Comparison of Intravitreal Bevacizumab Alone Versus Combined Bevacizumab and Macular Photocoagulation in Diabetic Macular Edema." Turkiye Klinikleri Journal of Ophthalmology 27, no. 3 (2018): 187–93. http://dx.doi.org/10.5336/ophthal.2017-57055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

HOU, Jing, Yong TAO, Yan-rong JIANG, Xiao-xin LI, and Lei GAO. "Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study." Chinese Medical Journal 122, no. 22 (2009): 2695–99. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.2009.22.004.

Full text

Abstract:

Background Branch retinal vein occlusion (BRVO) is a common retinal vascular disorder of the elderly and both intravitreal triamcinolone acetonide (TA) and intravitreal bevacizumab were reported to be effective. The purpose of this study was to compare intravitreal bevacizumab with intravitreal TA for the treatment of macular edema resulting from BRVO. Methods The retrospectively comparative interventional study included a bevacizumab group of 34 BRVO patients (1.25 mg bevacizumab) and a TA group of 34 BRVO patients (4.0 mg TA), and the two groups were matched by baseline best corrected visual

APA, Harvard, Vancouver, ISO, and other styles

31

Khalid, Iqra, Tayyaba Gul Malik, Hassan Tariq, and Usman Sajid. "Effect of intravitreal Bevacizumab on coagulation profile of patients with diabetic retinopathy." Pakistan Journal of Medical Sciences 41, no. 2 (2025): 355–58. https://doi.org/10.12669/pjms.41.2.10289.

Full text

Abstract:

Objectives: Intravitreal injections of Bevacizumab are widely used all over the world to treat Diabetic Retinopathy. However, there are thromboembolic events reported with its use. As blood coagulation is related with thromboembolism, the purpose of this study was to determine the effect of intravitreal injection of Bevacizumab on the coagulation profile of diabetic patients. Methods: It was a quasi-experimental study, conducted at Department of Ophthalmology, Lahore General Hospital from January 2023 to August 2023. Patients with treatment naïve proliferative DR and diabetic macular edema wer

APA, Harvard, Vancouver, ISO, and other styles

32

Hanna, Ramy M., Lama Abdelnour, Huma Hasnain, Umut Selamet, and Ira Kurtz. "Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab." SAGE Open Medical Case Reports 8 (January 2020): 2050313X2090703. http://dx.doi.org/10.1177/2050313x20907033.

Full text

Abstract:

Certain diabetic and hypertensive patients started on intravitreal vascular endothelial growth factor inhibition for diabetic retinopathy may experience worsening of hypertension and proteinuria. The etiology of this is the newly recognized absorption of intravitreally injected vascular endothelial growth factor inhibitors, and the susceptibility of patients with pre-existing renal disease to exacerbations depends on the degree of systemic absorption. There are eighteen reported cases of worsening hypertension, woresening proteinuria, worsening renal function, thrombotic microangiopathy, and g

APA, Harvard, Vancouver, ISO, and other styles

33

Schaal, Karen B., Alexandra E. Hoeh, Alexander Scheuerle, Florian Schuett, and Stefan Dithmar. "Intravitreal Bevacizumab for Treatment of Chronic Central Serous Chorioretinopathy." European Journal of Ophthalmology 19, no. 4 (2009): 613–17. http://dx.doi.org/10.1177/112067210901900415.

Full text

Abstract:

Purpose To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the treatment of intraretinal or subretinal fluid accumulation secondary to chronic central serous chorioretinopathy (CSC). Methods Twelve patients were treated with intravitreal injections of 2.5 mg bevacizumab at 6-to 8-week intervals until intraretinal or subretinal fluid resolved. Observation procedures were Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), ophthalmic examination, and optical coherence tomography (OCT), performed at 6- to 8-week intervals. Fluorescein angiog

APA, Harvard, Vancouver, ISO, and other styles

34

Nicoară, Simona Delia, Constanța Nascutzy, Cristina Cristian, et al. "Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity." Journal of Ophthalmology 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/102582.

Full text

Abstract:

Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it.Methods. This retrospective case series was carried out at the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania. It includes all the consecutive infants treated for ROP with one intravitreal bevacizumab injection, from January 1, 2009, throughout July 31, 2013. The follow-up continued for 60 weeks after injection. We recorded ROP classification, regression, gender, gestational age, birth weight, pos

APA, Harvard, Vancouver, ISO, and other styles

35

Ehrlich, Rita, Idit Dan, Iris Deitch, Ruth Axer-Siegel, and Karin Mimouni. "The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab." Ophthalmologica 235, no. 3 (2016): 133–36. http://dx.doi.org/10.1159/000444103.

Full text

Abstract:

Purpose: To investigate the response to intravitreal ranibizumab after failure of intravitreal bevacizumab in patients with diabetic macular edema (DME). Methods: Demographics, visual acuity (VA), central macular thickness (CMT), and HbA1C were retrospectively collected from DME patients treated with second-line intravitreal ranibizumab at a tertiary hospital in 2012-2013 and followed for at least 3 months. Results: Twenty-two patients (26 eyes) were included in the study, with a mean (±SD) age of 66 ± 8.1 years and followed for an average of 28.36 months. The mean number of intravitreal bevac

APA, Harvard, Vancouver, ISO, and other styles

36

Hasanreisoglu, Murat, Dov Weinberger, Karin Mimouni, et al. "Intravitreal Bevacizumab as an Adjunct Treatment for Neovascular Glaucoma." European Journal of Ophthalmology 19, no. 4 (2009): 607–12. http://dx.doi.org/10.1177/112067210901900414.

Full text

Abstract:

Purpose To assess the effect of adjunctive intravitreal bevacizumab treatment on neovascular glaucoma (NVG). Methods The medical records of all consecutive patients with NVG treated with intravitreal bevacizumab at our center from May 2006 to February 2008 were reviewed. The data collected included background features, findings on full ophthalmologic examination (including visual acuity, gonioscopy, and intraocular pressure), glaucoma medications prescribed, and additional procedures for glaucoma performed before and after bevacizumab injection. The interval between the diagnosis of NVG and in

APA, Harvard, Vancouver, ISO, and other styles

37

Lin, I.-Hung, Bo-I. Kuo, and Fang-Yu Liu. "Adjuvant Intravitreal Bevacizumab Injection for Choroidal and Orbital Metastases of Refractory Invasive Ductal Carcinoma of the Breast." Medicina 57, no. 5 (2021): 404. http://dx.doi.org/10.3390/medicina57050404.

Full text

Abstract:

The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known. Herein, we report the case of a 48-year-old woman with systemic chemotherapy-resistant choroidal and orbital metastases of the left eye originating from a stage IV invasive ductal carcinoma of the left breast. We describe the addition of a single intravitreal injection of bevacizumab in addition to treatment with systemic chemotherapy, hormonal therapy, and palliative radiotherapy. The patient’s outcome at

APA, Harvard, Vancouver, ISO, and other styles

38

Wu, Ziqiang, and Srinivas R. Srinivas R. "Effects on the Contralateral Eye After Intravitreal Bevacizumab and Ranibizumab Injections: A Case Report." Annals of the Academy of Medicine, Singapore 37, no. 7 (2008): 591–93. http://dx.doi.org/10.47102/annals-acadmedsg.v37n7p591.

Full text

Abstract:

Introduction: We report a case in which intravitreal bevacizumab and ranibizumab appeared to have effects in the contralateral, uninjected eye. Clinical Picture: An 83-year-old man with macular oedema from branch retinal vein occlusion (BRVO) in the right eye developed neovascular macular degeneration in the left eye. Intravitreal bevacizumab in the left eye improved macular oedema in the right eye temporarily before it recurred. Subsequently, intravitreal ranibizumab in the left eye also resulted in significant reduction of macular oedema in the right eye. Outcome: Vision and macular oedema i

APA, Harvard, Vancouver, ISO, and other styles

39

Hostovsky, Avner, Iris Moroz, and Gabriel Katz. "Aflibercept monotherapy or bevacizumab first for diabetic macular edema." Indian Journal of Ophthalmology 72, Suppl 2 (2024): S260—S264. http://dx.doi.org/10.4103/ijo.ijo_2107_23.

Full text

Abstract:

Purpose: Clinical outcome and switch patterns with bevacizumab first treatment strategy for patients with newly diagnosed neovascular age-related macular degeneration (nAMD). Methods: Retrospective observational study of the number of intravitreal injections of bevacizumab and treatment switch in patients who started intravitreal bevacizumab injections between January 1, 2016 and December 30, 2018. Results: From January 1 2016 to December 31 2018, 608 eyes of 565 patients started intravitreal injections of bevacizumab for a new diagnosis of nAMD. Average visual acuity (VA) at presentation was

APA, Harvard, Vancouver, ISO, and other styles

40

Rickmann, Annekatrin, Lina R. Paez, Maria della Volpe Waizel, et al. "Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages." PLOS ONE 16, no. 4 (2021): e0250587. http://dx.doi.org/10.1371/journal.pone.0250587.

Full text

Abstract:

Background To analyze the functional and anatomical outcome after vitrectomy with subretinal rtPA (recombinant tissue plasminogen activator) combined with or without an intravitreal Bevacizumab injection. Patients and methods Retrospective, consecutive case series of 31 pseudophakic patients with submacular hemorrhage (SMH) due to neovascular age-related macular degeneration (AMD) treated with vitrectomy, subretinal rtPA and pneumatic air displacement with or without an additional intravitreal Bevacizumab injection. The primary endpoints were best-corrected visual acuity (BCVA), and central ma

APA, Harvard, Vancouver, ISO, and other styles

41

Fikri, Handy Khairul, and Christina Yosephine Yudiathy Bangun. "Gambaran Karakteristik Dan Tajam Penglihatan Pada Pasien Diabetic Macular Edema (DME) Yang Mendapat Injeksi Bevacizumab Di Klinik Spesialis Mata SMEC Siantar Tahun 2021." Oftalmologi: Jurnal Kesehatan Mata Indonesia 4, no. 3 (2022): 51–58. http://dx.doi.org/10.11594/ojkmi.v4i3.38.

Full text

Abstract:

Pendahuluan: Retinopati diabetik adalah komplikasi diabetes yang paling umum. Diabetic Macula Edema (DME) adalah komplikasi independen dari retinopati diabetik dan terjadi pada sekitar 6,8% pasien DM. Salah satu patogenesis pada DME adalah karena peningkatan ekspresi VEGF. Selama beberapa tahun terakhir,anti Vaskular Endothelial Growth Factor (anti-VEGF) telah menjadi terapi lini pertama. Bevacizumab adalah anti-VEGF yang dapat meningkatkan Best Corrected Visual Acuity (BCVA) dan mengurangi Central Macular Thickness (CMT) pada pasien DME. Tujuan: mengetahui gambaran karakteristik pasien DME ya

APA, Harvard, Vancouver, ISO, and other styles

42

Bakhtiari, Elham, Majid Abrishami, Vahideh Nouzari, Faezeh Saffari, and Rahim Saffari. "Anterior segment changes in nonproliferative diabetic patient with macular edema treated by intravitreous bevacizumab injection." Medicine 104, no. 18 (2025): e41994. https://doi.org/10.1097/md.0000000000041994.

Full text

Abstract:

Currently, intravitreal bevacizumab is widely used for patients with intraocular neovascular disorders and macular edema. There are few studies about the effects of bevacizumab on anterior segment parameters and human cornea. The aim of this study was to evaluate the effects of intravitreal injection of bevacizumab on anterior chamber and central corneal thickness (CCT) during 3 months follow-up, using anterior segment optical coherence tomography. This longitudinal study was included 40 eyes of 20 patients. Patients received an intravitreal injection of 1.25 mg/0.05 mL bevacizumab. Anterior s

APA, Harvard, Vancouver, ISO, and other styles

43

Belin, Peter J., Andrew C. Lee, Giovanni Greaves, Jennifer Kosoy, and Ronni M. Lieberman. "The use of bevacizumab in pediatric retinal and choroidal disease: A review." European Journal of Ophthalmology 29, no. 3 (2019): 338–47. http://dx.doi.org/10.1177/1120672119827773.

Full text

Abstract:

The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.

APA, Harvard, Vancouver, ISO, and other styles

44

Yohendran, Jayshan, and Devinder Chauhan. "Erectile dysfunction following intravitreal bevacizumab." Middle East African Journal of Ophthalmology 17, no. 3 (2010): 281. http://dx.doi.org/10.4103/0974-9233.65497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Gurung, Babita, Eliya Shrestha, Hara Maya Gurung, et al. "Intravitreal Injection Bevacizumab: Main Indications." Acta Scientific Ophthalmology 4, no. 8 (2021): 37–39. http://dx.doi.org/10.31080/asop.2021.04.0360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Arevalo, J., and Rafael Garcia-Amaris. "Intravitreal Bevacizumab for Diabetic Retinopathy." Current Diabetes Reviews 5, no. 1 (2009): 39–46. http://dx.doi.org/10.2174/157339909787314121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Toklu, Yasin, Ozge Sarac, Sule Berk, and Saban Simsek. "Angioedema after intravitreal bevacizumab injection." Cutaneous and Ocular Toxicology 31, no. 1 (2012): 85–86. http://dx.doi.org/10.3109/15569527.2011.609207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Vasudev, Deepta, Michael P. Blair, John Galasso, Rashmi Kapur, and Thasarat Vajaranant. "Intravitreal Bevacizumab for Neovascular Glaucoma." Journal of Ocular Pharmacology and Therapeutics 25, no. 5 (2009): 453–58. http://dx.doi.org/10.1089/jop.2009.0036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Örnek, Kemal, and Tevfik Oğurel. "Intravitreal Bevacizumab for Diabetic Papillopathy." Journal of Ocular Pharmacology and Therapeutics 26, no. 2 (2010): 217–18. http://dx.doi.org/10.1089/jop.2009.0125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Yazdani, Shahin, Kamran Hendi, Mohammad Pakravan, Manijeh Mahdavi, and Mehdi Yaseri. "Intravitreal Bevacizumab for Neovascular Glaucoma." Journal of Glaucoma 18, no. 8 (2009): 632–37. http://dx.doi.org/10.1097/ijg.0b013e3181997211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!